WARNING: This product is for research use only, not for human or veterinary use.
MedKoo CAT#: 201931
Description: Alisertib, also known as MLN8237, is a second-generation, orally bioavailable, highly selective small molecule inhibitor of the serine/threonine protein kinase Aurora A kinase with potential antineoplastic activity. Aurora kinase inhibitor MLN8237 binds to and inhibits Aurora A kinase, which may result in disruption of the assembly of the mitotic spindle apparatus, disruption of chromosome segregation, and inhibition of cell proliferation.
MedKoo Cat#: 201931
Chemical Formula: C27H20ClFN4O4
Exact Mass: 518.11571
Molecular Weight: 518.9
Elemental Analysis: C, 62.49; H, 3.88; Cl, 6.83; F, 3.66; N, 10.80; O, 12.33
Alisertib, purity > 98%, is in stock. The same day shipping out after order is received.
Related CAS #: 1028486-06-7 (sodium anhydrous) 1208255-63-3 (sodium)
Synonym: MLN8237; MLN-8237; MLN 8237; alisertib.
IUPAC/Chemical Name: 4-((9-chloro-7-(2-fluoro-6-methoxyphenyl)-5H-benzo[c]pyrimido[4,5-e]azepin-2-yl)amino)-2-methoxybenzoic acid
InChi Key: ZLHFILGSQDJULK-UHFFFAOYSA-N
InChi Code: InChI=1S/C27H20ClFN4O4/c1-36-21-5-3-4-20(29)23(21)25-19-10-15(28)6-8-17(19)24-14(12-30-25)13-31-27(33-24)32-16-7-9-18(26(34)35)22(11-16)37-2/h3-11,13H,12H2,1-2H3,(H,34,35)(H,31,32,33)
SMILES Code: O=C(O)C1=CC=C(NC2=NC=C3C(C4=CC=C(Cl)C=C4C(C5=C(OC)C=CC=C5F)=NC3)=N2)C=C1OC
|Solvent||Max Conc. mg/mL||Max Conc. mM|
|Soluble in DMSO, not in water||100.0|
The following data is based on the product molecular weight 518.9 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.
|Concentration / Solvent Volume / Mass||1 mg||5 mg||10 mg|
|1 mM||1.15 mL||5.76 mL||11.51 mL|
|5 mM||0.23 mL||1.15 mL||2.3 mL|
|10 mM||0.12 mL||0.58 mL||1.15 mL|
|50 mM||0.02 mL||0.12 mL||0.23 mL|
1. Preparation of [(phenylpyrimidobenzazepinyl)amino]methoxybenzoic acid derivatives for us as antitumor agents. Claiborne, Christopher F.; Sells, Todd B.; Stroud, Stephen G. (Millennium Pharmaceuticals, Inc., USA). PCT Int. Appl. (2008), 43pp. CODEN: PIXXD2 WO 2008063525 A1 20080529 . Patent written in English. Application: WO 2007-US23948 20071114. Priority: US 2006-859340 20061116.
MLN-8237 is an Aurora A kinase blocker designed to disrupt the cycle of cancer cells. It is being tested in several types of cancer as monotherapy and in combination with different chemotherapy regimens. Millennium expects MLN-8237 to progress to mid-stage trials later in 2009. If MLN-8237 survives the clinical trial process, it may become the first approved therapy in the Aurora A kinase blocker class. Millennium is in a race, however, with research and development divisions at other pharmaceutical companies that are testing their own Aurora A kinase blockers. see: www.hcplive.com/media/pdf/May09_09PFN.pdf .
Current developer: Millennium Pharmaceuticals, Inc.